3-Year landmark overall survival and quality-adjusted overall survival with RP1 combined with nivolumab in anti–PD-1–failed melanoma: Results from the IGNYTE trial (SITC 2026) - Oct 2, 2026 - Abstract #503; Pres time: Nov 6, 2026; No abstract available
Clinical • Melanoma • Oncology • Solid Tumor
|
|
Gino In; Dirk Schadendorf; Tawnya Bowles; Joseph Sacco; Caroline Robert; Judith Michels; Bartosz Chmielowski; Georgia Beasley; Michael Wong; Trisha Wise-Draper; Jiaxin Niu; Mohammed Milhem; Céleste Lebbé; Caroline Gaudy-Marqueste; Adel Samson; Eva Muñoz Couselo; Ari VanderWalde; Jason Chesney; Chris Poole; Jeannie Hou; Moran Mishal; Katrine Wallace
|